Daprodustat APIs form a part of Loncom Pharma's commitment to advancing treatment for anemia associated with chronic kidney disease. These APIs function as HIF prolyl-hydroxylase inhibitors, stimulating erythropoiesis and reducing the need for traditional erythropoietin-stimulating agents.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
